Lung (Non-Small Cell) Cancer: S1900A

S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (A LUNGMAP Treatment Trial)


There are several investigational treatments that are being tested in various sub-studies as part of the LUNGMAP screening trial. This trial is for patients who have already received the information on the results of the biomarker testing as part of the LUNGMAP screening trial. Patients eligible for this study have a tumor sample that is LOH-positive (Loss of Heterozygosity, which is a genomic variation in the make-up of the cancer cells) or BRCA-positive (a mutation in either the BRCA1 or BRCA2 genes, which are tumor suppressor genes). LOH and BRCA are changes in genes that may make the cancer respond to a poly (ADP) ribose polymerase (PARP) inhibitor. A PARP inhibitor is a drug that blocks the PARP enzyme in cells. The PARP enzyme helps cancer cells to be able to repair, and inhibiting this enzyme can cause cancer cells to die. For this sub-study, patients will be assigned to treatment with an investigational drug called rucaparib, a PARP inhibitor.  Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

This sub-study is associated with the LUNGMAP screening protocol.

Click here for more information from the National Cancer Institute.


1. Genesis Cancer Care Institute

1401 W. Central Park Ave.

Davenport, IA 52804

Phone Number: 563-421-1900

2. Genesis Cancer Clinic-Silvis

801 Illini Dr.

Silvis, IL 61282

Phone Number: 563-421-1900

3. Iowa Cancer Specialists

1750 E. 53rd St.

Davenport, IA 52807

Phone Number: 563-345-4325

Clinical Trial Categories

  • Cancer
  • Lung (Non-Small Cell)
Kim Turner, R.N. at 563-421-1908


  • Various Locations

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office